Coherus and Zumutor Biologics Announce Clinical Collaboration for Phase 1 Trial of ZM008 with LOQTORZI

M&A · Partnership
โดย GlobeNewswire·Read original
Summary · why it matters

Coherus Oncology and Zumutor Biologics have entered a clinical collaboration and supply agreement to evaluate ZM008, a novel anti-LLT1 monoclonal antibody, in combination with LOQTORZI, a next-generation PD-1 inhibitor, in a Phase 1 trial. The study, identified as NCT06451497, will enroll up to 45 patients across dose-escalation and expansion cohorts in the United States, targeting colorectal, head and neck, non-small cell lung cancer, clear cell renal cell carcinoma, urothelial cancers, and other solid tumors. Under the agreement, Coherus will supply LOQTORZI while Zumutor sponsors the trial, with each company retaining all commercial rights to their respective compounds. ZM008, discovered using Zumutor's proprietary INABLR platform, has shown a favorable safety profile and clinical benefit in metastatic patients previously treated with immune checkpoint inhibitors in an ongoing monotherapy study. The collaboration aims to expand potential LOQTORZI indications beyond nasopharyngeal carcinoma and strengthen the clinical data package in the U.S. through cost-efficient drug supply agreements.

Impact on stocks 1

Biotech & Genomic Medicine▲ · 1 stocks
Coherus BioSciences Inc
CHRS
▲ PositiveTechnologyrelevance

Coherus enters clinical collaboration to test its PD-1 inhibitor LOQTORZI in combination with ZM008, potentially expanding indications beyond nasopharyngeal carcinoma.

Theme Impact 2

Off-coverage companies 1

Zumutor Biologics Inc.Private▲ Positive
Technologyrelevance

Zumutor's ZM008 enters Phase 1 trial in combination with LOQTORZI, advancing its pipeline and validating its INABLR platform.

Related news

▲2

Akeso Wins China Phase I Clearance for AK158D1 Bispecific ADC

Akeso has secured Phase I clinical trial clearance in China for AK158D1, a bispecific antibody drug conjugate targeting EGFR and TROP2 in advanced solid tumors. The clearance puts fresh attention on the company's pipeline as it pushes deeper into IO2.0 and ADC2.0. Akeso's shares recently traded at HK$90.5, up 3.37% over 90 days but down 20.12% year to date, against a consensus analyst price target of HK$158.28, with the most bullish target at HK$226.04 and the most bearish at HK$125.08. The company remains exposed to execution setbacks given its reliance on a handful of key drugs and a current net loss of CN¥967.2 million.
9926.HK ▲
Biotech & Genomic Medicine ▲
Simply Wall St·9hRead more →
▲2

Merck's KEYTRUDA Plus Padcev Wins CHMP Backing for EU Bladder Cancer

Merck received a positive opinion from the European Medicines Agency's CHMP for KEYTRUDA plus Padcev in muscle-invasive bladder cancer. The CHMP backed the combination as perioperative therapy for adults with resectable muscle-invasive bladder cancer in the European Union. If endorsed by the European Commission, the regimen would be the first PD-1 inhibitor plus antibody-drug conjugate option for this setting in Europe. The addressable group in Europe is relatively concentrated but clinically high need, with bladder cancer cases estimated at about 224,700 in 2022, roughly 25% of them classified as muscle invasive. The key near-term marker is the European Commission ruling expected by the fourth quarter of 2026, since the CHMP only issues recommendations.
MRKMRK.XETRA
Biotech & Genomic Medicine ▲
Simply Wall St·11hRead more →
impact 4

FDA Grants Full Approval to Lilly's Inluriyo Plus Verzenio for ESR1-Mutated Breast Cancer

Eli Lilly and Company announced that the U.S. Food and Drug Administration has granted full approval to Inluriyo, or imlunestrant, in combination with Verzenio, or abemaciclib, for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy. The decision rests on the Phase 3 EMBER-3 trial, in which the combination doubled median progression-free survival versus Inluriyo alone, at 11.1 months versus 5.5 months, with a hazard ratio of 0.53 and a 95% confidence interval of 0.35 to 0.80, among the 159 patients with ESR1-mutated metastatic breast cancer. In that trial, 92 patients received Inluriyo alone and 67 received the combination after an aromatase inhibitor, with or without a CDK4/6 inhibitor, in either the adjuvant or metastatic setting. The approval marks the second FDA clearance for Inluriyo in less than a year, following its September 2025 monotherapy approval for the same ER-positive, HER2-negative, ESR1-mutated metastatic population. Inluriyo is also being studied in the Phase 3 EMBER-4 trial in the adjuvant setting for ER-positive, HER2-negative early-stage breast cancer, the largest adjuvant oral SERD trial with more than 8,000 patients enrolled across 650-plus sites in more than 30 countries, with initial results anticipated in 2027. The combination is now available in the United States.
LLY ▲
Biotech & Genomic Medicine ▲
PR Newswire·16hRead more →
© 2026 MarketDXNews